Dendritic cells in hematologic malignancies a brief review of immunoregulation to new perspectives
Biochemia medica · 15.06.2026 · 36 (2) · 185-198
DOI: 10.11613/bm.2026.020501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemia medica, online erschienen am 15.06.2026. Verfasst von Gabriel Barroso de Almeida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, Bahia, Brazil. Hauptthemen laut MEDLINE: Dendritic Cells, Hematologic Neoplasms, Leukemia, Myeloid, Acute, Immunomodulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dendritic cells (DCs) are essential immune system sentinels, playing a key role in activating naïve T cells against leukemic cells. They have an immunomodulatory function, promoting an immune response and, at the same time, regulating immune tolerance to avoid excessive reactions. Plasmacytoid dendritic cell (pDC) neoplasms are a complex group of disorders, and among the subtypes, acute myeloid leukemia (AML) with pDC dermatosis (AML-pDC) stands out. In this context, pDCs can play an immunomodulatory role by inhibiting or promoting immune responses and acting as tumor progenitors since, in some cases, they can collaborate with the tumor microenvironment, favoring immune evasion and proliferation. However, the clinical significance of pDC in AML is not fully understood. Studies suggest that the interaction of pDCs with the leukemic microenvironment may contribute to disease progression by impairing the immune system’s ability to control tumor cells. Understanding the role of DCs in neoplasia is crucial, as it provides important insights for new studies seeking advances in innovative therapeutic strategies, such as dendritic cell vaccines. These vaccines are promising, with low toxicity and the potential to improve the prognosis of individuals affected by AML, stimulating an effective immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immunology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, Bahia, Brazil.
- Laboratory of Acute Leukemia Genetics, National Cancer Institute, Rio de Janeiro, Brazil.
Zitieren
APA
de Almeida, G. B., Dos Santos, M. M., de Oliveira Barbosa, D., Conceição, R. R., de Almeida Lopes, B., de Melo Santos, H. H., & Marchioro, S. B. (2026). Dendritic cells in hematologic malignancies a brief review of immunoregulation to new perspectives. Biochemia medica, 36(2), 185-198. https://doi.org/10.11613/bm.2026.020501
Vancouver
de Almeida GB, Dos Santos MM, de Oliveira Barbosa D, Conceição RR, de Almeida Lopes B, de Melo Santos HH, et al. Dendritic cells in hematologic malignancies a brief review of immunoregulation to new perspectives. Biochemia medica. 2026;36(2):185-198. doi:10.11613/bm.2026.020501
BibTeX
@article{deAlmeida2026,
author = {de Almeida, Gabriel Barroso and Dos Santos, Mariane Melo and de Oliveira Barbosa, Dyjaene and Conceição, Rogério Reis and de Almeida Lopes, Bruno and de Melo Santos, Herbert Henrique and Marchioro, Silvana Beutinger},
title = {Dendritic cells in hematologic malignancies a brief review of immunoregulation to new perspectives},
journal = {Biochemia medica},
year = {2026},
volume = {36},
number = {2},
pages = {185--198},
doi = {10.11613/bm.2026.020501}
}
EUVIMED